Back to Results

Lebrikizumab AD

Title A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis
Therapeutic Area Atopic Dermatitis
Principal Investigator David Rosmarin, MD
Min Age 18 Years
Max Age 55 Years
Gender All
Contact Nicole Dumont
617 636 7462
More Information


Phase 3, randomized, double-blind, placebo-controlled study to assess the impact of lebrikizumab on vaccine immune responses in adult patients with moderate-to-severe atopic dermatitis (AD). This study will evaluate the effect of lebrikizumab treatment on 2 vaccines commonly used in adults with moderate to severe AD

Study Details

Inclusion Criteria

  • Have chronic AD that has been present for ≥1 year before the screening visit;
  • Have ≥10% Body Surface Area (BSA) of AD involvement at the baseline visit;
  • History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.

Exclusion Criteria

  • Have a history of anaphylaxis;
  • Have an uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids;
  • Have an active chronic or acute infection requiring treatment with systemic antibiotics,antivirals, antiparasitics, antiprotoxoals, or antifungals within 2 weeks before the baseline visit

Study Requirements

10 visit over 16 weeks, with the option to enroll into an open-label long term extension study.